PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2025-12-11

Date Title Company
11-Dec-2025 Valinor Raises $13 Million to Increase Clinical Trial Success Rates with Proprietary ML Models Businesswire
11-Dec-2025 Accenture Invests in Ryght AI to Help Life Sciences Companies Transform Clinical Research with Agentic AI Businesswire
11-Dec-2025 U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma Businesswire
11-Dec-2025 ACRO Announces 2026 Officers Businesswire
11-Dec-2025 Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization ACCESS Newswire
11-Dec-2025 NHS Confederation responds to government offer to resident doctors in England NHS Confederation
11-Dec-2025 Pharmaffiliates Honoured with Three Prestigious SME–Empowering India Awards together Pharmaffiliates Private Limited
11-Dec-2025 HomeAid Celebrates the Launch of Its 20th Affiliate in the Delaware Valley Area ACCESS Newswire
11-Dec-2025 Particology joins £8.2M API crystallisation project to revolutionise medicines manufacturing Particology Ltd
11-Dec-2025 Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer Actithera
11-Dec-2025 Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting Lundbeck
11-Dec-2025 Ryvu Therapeutics Presents New Clinical Data from RIVER-81 and POTAMI-61 Studies of Romaciclib (RVU120) at the 2025 American Society of Hematology (ASH) Annual Meeting Ryvu Therapeutics
11-Dec-2025 Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology Oncoinvent
11-Dec-2025 Poolbeg Pharma plc - POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme Poolbeg Pharma
11-Dec-2025 Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa Xinnate
11-Dec-2025 Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome Fibrocor Therapeutics
11-Dec-2025 ProBioGen and Spica Therapeutics Announce Collaboration on GlymaxX-Enhanced CLD for Spica’s Clinical Development Candidate ST101 ProBioGen and Spica Therapeutics
11-Dec-2025 WORLD’S LEADING ANTIMALARIAL PRODUCT DEVELOPMENT PARTNERSHIP JOINS IICON CONSORTIUM IICON CONSORTIUM
11-Dec-2025 VPAG payment rate for newer medicines will be 14.5% in 2026 VPAG
11-Dec-2025 LIV Recovery Center Expands Family Care & Support to Address Hidden Impact of Addiction ACCESS Newswire